Key facts
- Gordian Biotechnology’s last known valuation is $170.0M (Dec 2021).
- It has raised $60.0M across 1 recorded rounds; the latest was Seed Round ($1.5M) in Apr 2020.
- Notable investors include Metaplanet Holdings, Founders Fund, StartX (US), K5 Global, Caffeinated Capital — 32 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 32 names
- ·Watchlist + deal alerts for Gordian Biotechnology
Funding rounds
1 roundsAbout Gordian Biotechnology
Developer of a gene therapy discovery platform designed to improve research for complex diseases related to aging. The company's platform researches and develops therapeutic drugs that can prevent premature aging in humans, enabling doctors to cure age-related diseases and patients to improve their skin conditions.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 39
- Website
- gordian.bio/
- Ownership
- Privately Held (backing)
Gordian Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gordian Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gordian Biotechnology in its N-PORT filings yet. We sweep new filings monthly.